文献速递母胎医学

产前诊断当前争议:低风险人群使用cfDNA筛查单基因病的临床应用时机

Current controversy in prenatal diagnosis: The use of cfDNA to screen for monogenic conditions in low risk populations is ready for clinical use.
PubMed 文献 · Prenat Diagn · 2023-11-22

本文总结第27届国际产前诊断与治疗会议上关于低风险孕妇使用单基因病无创产前检测(sgNIPT)的辩论。支持方认为可识别无需伴侣检测的常染色体隐性病受累胎儿及超声正常时易漏诊的常染色体显性病胎儿,反对方指出传统携带者筛查已可覆盖、缺乏临床验证研究、阴性结果可能造成虚假安心、阳性结果可能导致不必要侵入性操作。基于讨论和听众投票,认为对全部低风险孕妇提供sgNIPT似乎为时过早,需进一步临床验证研究。

要点

  • 低风险孕妇使用sgNIPT支持方强调可识别无需伴侣检测的常染色体隐性病受累胎儿。
  • 反对方指出常染色体显性病sgNIPT完全缺乏临床验证研究。
  • 基于讨论和听众投票,对全部低风险孕妇提供sgNIPT似乎为时过早。

核心结论

  • 基于讨论和听众投票,对全部低风险孕妇提供sgNIPT似乎为时过早,需进一步临床验证研究后方可广泛实施。

研究设计与样本

  • 本文为第27届国际产前诊断与治疗会议上关于低风险妊娠使用sgNIPT的辩论总结,双方专家分别提出支持与反对论据。

主要发现

  • 支持常染色体隐性病sgNIPT的论据是无需伴侣参与检测即可识别受累妊娠。
  • 支持常染色体显性病sgNIPT的论据包括识别超声正常时产前未检出或妊娠后期才出现胎儿异常的受累胎儿、尊重患者自主权和患者对信息的需求。
  • 反对sgNIPT的论据包括许多地区已可开展传统携带者筛查、sgNIPT附加价值未明确证实、常染色体显性病sgNIPT完全缺乏临床验证研究、阴性结果存在虚假安心风险、假阳性结果可能导致不必要侵入性操作。

局限性

  • 原文指出常染色体显性病sgNIPT完全缺乏临床验证研究。
  • 原文指出阴性结果存在虚假安心的风险,假阳性结果可能导致不必要的侵入性操作。
  • 原文指出sgNIPT在低风险人群中的附加价值尚未明确证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Noninvasive cfDNA testing for monogenic disorders (sgNIPT) has become integrated into the care of pregnant women at increased risk based on carrier status, known family history, or ultrasound anomalies. The availability of commercial tests for common autosomal recessive and de novo autosomal dominant conditions has led to the use of these tests in low-risk pregnancies. However, is the technology ready for use in this low-risk population? This report is a summary of the debate on this topic at the 27th International Conference on Prenatal Diagnosis and Therapy. Both expert debaters provided strong arguments in favor and against the use of sgNIPT in low-risk pregnancies. The argument in favor of sgNIPT for autosomal recessive conditions is that it allows the identification of affected pregnancies without the need for involving the partner in testing. Arguments for sgNIPT for autosomal dominant conditions include identification of affected fetuses that would have either presented later in pregnancy with fetal anomalies or not been detected prenatally given normal ultrasounds, respect for patient autonomy and patient desire for information. Strong arguments were made against offering sgNIPT screening. Given that traditional carrier screening for recessive conditions can be carried out in many jurisdictions, the added value of sgNIPT has not been clearly demonstrated. Arguments against sgNIPT for autosomal dominant conditions included the total lack of clinical validation studies and the risk of false reassurance in cases of negative results and unnecessary invasive procedures in cases of false positive results. Although there is a desire to take advantage of new technologies to improve the detection of monogenic disorders in low-risk populations, based on the discussion and the audience vote, it appears premature to offer sgNIPT to all low risk pregnant women. Further clinical validation studies are needed prior to broad implementation.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Vora NL, Langlois S, Chitty LS, et al. Current controversy in prenatal diagnosis: The use of cfDNA to screen for monogenic conditions in low risk populations is ready for clinical use. Prenat Diagn. 2023. PMID: 37991340. doi:10.1002/pd.6469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。